{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:54:50Z","timestamp":1793764490698,"version":"4.6.1"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2020,1,31]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>High-density lipoprotein (HDL) levels are inversely associated with cardiovascular risk. Cholesteryl ester transfer protein inhibition with evacetrapib results in a marked increase in HDL and reduction in low-density lipoprotein (LDL) levels. We evaluated the impact of treatment with evacetrapib versus placebo in the subset of 8236 patients with diabetes mellitus (DM) enrolled in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Time to first occurrence of any component of the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, revascularization, and hospitalization for unstable angina was compared among patients with DM randomized to treatment with evacetrapib (n=4127) or placebo (n=4109) over a median of 26 months of follow-up. The mean baseline LDL at initiation was 80\u2009mg\/dL with a mean baseline HDL of 44\u2009mg\/dL. In patients with DM, evacetrapib resulted in a 131% mean increase in HDL levels and a 32% mean decrease in LDL at 3 months that was sustained during the course of the trial. At 6 months, hemoglobin A1c (HbA1c) levels were lower with evacetrapib than placebo (7.08% vs 7.15%, p=0.023). Composite event rates were higher in patients with DM than without DM (Kaplan-Meier estimates: 15.2% vs 10.6%, HR 1.46, 95%\u2009CI 1.30 to 1.64, p&lt;0.001). In the DM group, event rates for the composite endpoint (14.5% evacetrapib vs 16% placebo, HR 0.95, 95%\u2009CI 0.85 to 1.07, p=0.38) and individual components of the composite were similar for both evacetrapib and placebo groups. No significant treatment interaction between treatment assignment and diabetes status was noted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite a favorable increase in HDL, and decreases in LDL and HbA1c levels in patients with DM, we observed no benefits of treatment with evacetrapib on prespecified clinical outcomes in this high-risk population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2019-000943","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T05:15:25Z","timestamp":1584335725000},"page":"e000943","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-2677","authenticated-orcid":false,"given":"Venu","family":"Menon","sequence":"first","affiliation":[{"name":"Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4413-5439","authenticated-orcid":false,"given":"Anirudh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyang R","family":"Patel","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"St John","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Riesmeyer","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govinda","family":"Weerakkody","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Ruotolo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy E","family":"Wolski","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"McErlean","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"Cremer","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Nissen","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,15]]},"reference":[{"key":"2025073112250175000_8.1.e000943.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht108"},{"key":"2025073112250175000_8.1.e000943.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008862"},{"key":"2025073112250175000_8.1.e000943.3","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(96)05852-2"},{"key":"2025073112250175000_8.1.e000943.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380200073024"},{"key":"2025073112250175000_8.1.e000943.5","doi-asserted-by":"publisher","DOI":"10.1161\/hc3501.095214"},{"key":"2025073112250175000_8.1.e000943.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064278"},{"key":"2025073112250175000_8.1.e000943.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.23.2777"},{"key":"2025073112250175000_8.1.e000943.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60312-2"},{"key":"2025073112250175000_8.1.e000943.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.108.817304"},{"key":"2025073112250175000_8.1.e000943.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht571"},{"key":"2025073112250175000_8.1.e000943.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"2025073112250175000_8.1.e000943.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"2025073112250175000_8.1.e000943.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1649"},{"key":"2025073112250175000_8.1.e000943.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609581"},{"key":"2025073112250175000_8.1.e000943.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.09.007"},{"key":"2025073112250175000_8.1.e000943.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"2025073112250175000_8.1.e000943.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"2025073112250175000_8.1.e000943.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"2025073112250175000_8.1.e000943.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"2025073112250175000_8.1.e000943.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"2025073112250175000_8.1.e000943.21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"2025073112250175000_8.1.e000943.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"2025073112250175000_8.1.e000943.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"2025073112250175000_8.1.e000943.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"2025073112250175000_8.1.e000943.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706628"},{"key":"2025073112250175000_8.1.e000943.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206797"},{"key":"2025073112250175000_8.1.e000943.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.09.013"},{"key":"2025073112250175000_8.1.e000943.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001689"},{"key":"2025073112250175000_8.1.e000943.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409065"},{"key":"2025073112250175000_8.1.e000943.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706444"},{"key":"2025073112250175000_8.1.e000943.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"2025073112250175000_8.1.e000943.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"2025073112250175000_8.1.e000943.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300955"},{"key":"2025073112250175000_8.1.e000943.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32290-0"},{"key":"2025073112250175000_8.1.e000943.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"2025073112250175000_8.1.e000943.36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.018259"},{"key":"2025073112250175000_8.1.e000943.37","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308055"},{"key":"2025073112250175000_8.1.e000943.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.14568"},{"key":"2025073112250175000_8.1.e000943.39","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the Fourier randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2019-000943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:25:07Z","timestamp":1753989907000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2019-000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,15]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bmjdrc-2019-000943"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2019-000943","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}